首页 > 最新文献

Reports of Practical Oncology and Radiotherapy最新文献

英文 中文
Definitive chemo-radiotherapy in cervical oesophageal cancer: a comprehensive review of literature. 宫颈食道癌的确定性放化疗:文献综述。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.100777
Ankita Mehta, Rohit Avinash Vadgaonkar, Shirley Lewis, Umesh Mahantshetty, J P Agarwal

Background and objectives: Despite decades of experience with definitive chemo-radiotherapy (CRT) in cervical oesophageal cancer (CEC), the loco-regional control and survival outcomes are dismal. This review evaluated the outcomes of various treatment strategies being commonly utilized.

Materials and methods: A literature review was conducted to identify relevant articles on CEC published from years 2000-2023 addressing the predefined key questions. These questions focussed on the comparative outcomes of various primary treatment approaches (surgery, CRT, or trimodality treatment) and the radiation dose schedules, volumes, and techniques.

Results: CRT is the standard approach for treatment for CEC so far. The potential role of surgery and trimodality approach in settings of evolving surgical approaches needs to be validated. The high dose schedules that are preferentially practiced in CEC have not shown any benefit in improving the disease outcomes over the standard dose schedule of 50.4 Gy. The target volume delineation practice of elective nodal irradiation (ENI) does not have a proven benefit over the involved field irradiation (IFI). The limited evidence on radiation techniques suggests that intensity-modulated radiotherapy/volumetric-modulated arc therapy (IMRT/VMAT) techniques can improve toxicity profile over three-dimensional conformal radiotherapy (3DCRT), but no advantage proven in disease outcomes so far.

Conclusion: This review will guide clinicians in decision-making for the management of this relatively rare entity and the directions for future research in these areas. Future large-scale multicentre prospective studies are needed for validating and standardizing our current practices and exploring potential options to improve the outcomes.

背景和目的:尽管宫颈食管癌(CEC)的确定性化疗放疗(CRT)已有几十年的经验,但局部区域控制和生存结果却令人沮丧。本综述评估了目前常用的各种治疗策略的效果:我们进行了文献综述,以确定 2000-2023 年间发表的有关 CEC 的相关文章,并回答了预先确定的关键问题。这些问题集中在各种主要治疗方法(手术、CRT 或三联疗法)以及放射剂量计划、剂量和技术的比较结果上:结果:迄今为止,CRT 是治疗 CEC 的标准方法。结果:迄今为止,CRT 是治疗 CEC 的标准方法。在手术方法不断发展的情况下,手术和三联疗法的潜在作用有待验证。与 50.4 Gy 的标准剂量相比,CEC 首选的高剂量方案在改善疾病预后方面并未显示出任何益处。与介入野照射(IFI)相比,选择性结节照射(ENI)的靶体积划定实践并未证明有任何益处。放疗技术方面的有限证据表明,调强放疗/容积调强弧形放疗(IMRT/VMAT)技术与三维适形放疗(3DCRT)相比,可以改善毒性状况,但迄今为止尚未证实在疾病预后方面有任何优势:本综述将指导临床医生对这一相对罕见的疾病做出治疗决策,并为这些领域的未来研究指明方向。未来需要开展大规模多中心前瞻性研究,以验证和规范我们目前的做法,并探索改善疗效的潜在方案。
{"title":"Definitive chemo-radiotherapy in cervical oesophageal cancer: a comprehensive review of literature.","authors":"Ankita Mehta, Rohit Avinash Vadgaonkar, Shirley Lewis, Umesh Mahantshetty, J P Agarwal","doi":"10.5603/rpor.100777","DOIUrl":"10.5603/rpor.100777","url":null,"abstract":"<p><strong>Background and objectives: </strong>Despite decades of experience with definitive chemo-radiotherapy (CRT) in cervical oesophageal cancer (CEC), the loco-regional control and survival outcomes are dismal. This review evaluated the outcomes of various treatment strategies being commonly utilized.</p><p><strong>Materials and methods: </strong>A literature review was conducted to identify relevant articles on CEC published from years 2000-2023 addressing the predefined key questions. These questions focussed on the comparative outcomes of various primary treatment approaches (surgery, CRT, or trimodality treatment) and the radiation dose schedules, volumes, and techniques.</p><p><strong>Results: </strong>CRT is the standard approach for treatment for CEC so far. The potential role of surgery and trimodality approach in settings of evolving surgical approaches needs to be validated. The high dose schedules that are preferentially practiced in CEC have not shown any benefit in improving the disease outcomes over the standard dose schedule of 50.4 Gy. The target volume delineation practice of elective nodal irradiation (ENI) does not have a proven benefit over the involved field irradiation (IFI). The limited evidence on radiation techniques suggests that intensity-modulated radiotherapy/volumetric-modulated arc therapy (IMRT/VMAT) techniques can improve toxicity profile over three-dimensional conformal radiotherapy (3DCRT), but no advantage proven in disease outcomes so far.</p><p><strong>Conclusion: </strong>This review will guide clinicians in decision-making for the management of this relatively rare entity and the directions for future research in these areas. Future large-scale multicentre prospective studies are needed for validating and standardizing our current practices and exploring potential options to improve the outcomes.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"391-408"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forecasting model for qualitative prediction of the results of patient-specific quality assurance based on planning and complexity metrics and their interrelations. Pilot study. 基于计划性和复杂性指标及其相互关系的患者质量保证结果定性预测模型。试点研究。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.101093
Tomasz Piotrowski, Adam Ryczkowski, Petros Kalendralis, Marcin Adamczewski, Piotr Sadowski, Barbara Bajon, Marta Kruszyna-Mochalska, Agata Jodda

Background: The purpose was to analyse the interrelations between planning and complexity metrics and gamma passing rates (GPRs) obtained from VMAT treatments and build the forecasting models for qualitative prediction (QD) of GPRs results.

Materials and method: 802 treatment arcs from the plans prepared for the head and neck, thorax, abdomen, and pelvic cancers were analysed. The plans were verified by portal dosimetry and analysed twice using the gamma method with 3%|2mm and 2%|2mm acceptance criteria. The tolerance limit of GPR was 95%. Red, yellow, and green QDs were established for GPR examination. The interrelations were examined, as well as the analysis of effective differentiation of QD. Three models for QD forecasting based on discriminant analysis (DA), random decision forest (RDF) methods, and the hybrid model (HM) were built and evaluated.

Results: Most of the interrelations were small or moderate. The exception is correlations of the join function with the average number of monitor units per control point (R = 0.893) and the beam aperture with planning target volume (R = 0.897). While many metrics allow for the effective separation of the QDs from each other, the study shows that predicting the values of the QD is possible only through multi-component forecasting models, of which the HM is the most accurate (0.894).

Conclusion: Of the three models explored in this study, the HM, which uses DA methods to predict red QD and RDF methods to predict green and yellow QDs, is the most promising one.

研究背景:材料与方法:分析了头颈部、胸部、腹部和盆腔癌症治疗计划中的802条治疗弧线。这些计划通过门静脉剂量测定进行验证,并使用伽马射线法进行了两次分析,接受标准分别为 3%|2mm 和 2%|2mm。GPR 的容限为 95%。为 GPR 检查建立了红色、黄色和绿色 QD。研究了相互关系,并分析了 QD 的有效区分。建立并评估了基于判别分析(DA)、随机决策森林(RDF)和混合模型(HM)的三种 QD 预测模型:结果:大多数相互关系较小或适中。例外情况是连接功能与每个控制点的平均监控单元数相关(R = 0.893),光束孔径与规划目标体积相关(R = 0.897)。虽然许多指标可以有效地将 QD 相互分离,但研究表明,只有通过多成分预测模型才能预测 QD 的值,其中 HM 是最准确的(0.894):在本研究探索的三种模型中,使用 DA 方法预测红色 QD,使用 RDF 方法预测绿色和黄色 QD 的 HM 是最有前途的模型。
{"title":"Forecasting model for qualitative prediction of the results of patient-specific quality assurance based on planning and complexity metrics and their interrelations. Pilot study.","authors":"Tomasz Piotrowski, Adam Ryczkowski, Petros Kalendralis, Marcin Adamczewski, Piotr Sadowski, Barbara Bajon, Marta Kruszyna-Mochalska, Agata Jodda","doi":"10.5603/rpor.101093","DOIUrl":"10.5603/rpor.101093","url":null,"abstract":"<p><strong>Background: </strong>The purpose was to analyse the interrelations between planning and complexity metrics and gamma passing rates (GPRs) obtained from VMAT treatments and build the forecasting models for qualitative prediction (QD) of GPRs results.</p><p><strong>Materials and method: </strong>802 treatment arcs from the plans prepared for the head and neck, thorax, abdomen, and pelvic cancers were analysed. The plans were verified by portal dosimetry and analysed twice using the gamma method with 3%|2mm and 2%|2mm acceptance criteria. The tolerance limit of GPR was 95%. Red, yellow, and green QDs were established for GPR examination. The interrelations were examined, as well as the analysis of effective differentiation of QD. Three models for QD forecasting based on discriminant analysis (DA), random decision forest (RDF) methods, and the hybrid model (HM) were built and evaluated.</p><p><strong>Results: </strong>Most of the interrelations were small or moderate. The exception is correlations of the join function with the average number of monitor units per control point (R = 0.893) and the beam aperture with planning target volume (R = 0.897). While many metrics allow for the effective separation of the QDs from each other, the study shows that predicting the values of the QD is possible only through multi-component forecasting models, of which the HM is the most accurate (0.894).</p><p><strong>Conclusion: </strong>Of the three models explored in this study, the HM, which uses DA methods to predict red QD and RDF methods to predict green and yellow QDs, is the most promising one.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"318-328"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose escalation with simultaneous integrated boost for un-methylated multiple glioblastoma. 对未甲基化多发性胶质母细胞瘤进行剂量升级,同时进行综合治疗。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.100385
Ory Haisraely, Maayan Sivan, Zvi Symon, M Ben-Ayun, L Tsvang, J Kraitman, S Dubinsky, M Siman-Tov, D Benjamin, Yaacov Lawrence, Zvi Cohen, Anton Wohl, Thila Kaisman-Elbaz, Alisa Taliansky

Background: Simultaneous involvement of multiple distinct brain regions occurs in 2-5% of all high-grade gliomas (HGG) and is associated with poor prognosis. Whereas radiotherapy (RT) is an important and well-established treatment for high-grade glioma, the role of dose-escalated radiotherapy has yet to be established. In this case series, we report upon the dosimetry, adverse effects, and response in patients with multiple un-methylated high-grade gliomas receiving dose-escalated radiation.

Materials and methods: We reviewed charts of patients with multifocal high grade glioma treated at our institution since January 2022. All patients had stereotactic biopsies after an magnetic resonance imaging (MRI) contrast-enhanced with T1, T2, FLAIR sequences and were discussed in a multidisciplinary oncology team. MGMT-positive patients received either TMZ alone or RT with TMZ and were excluded from this analysis. Un-methylated patients received dose-escalated RT without temezolamide (TMZ). Following computed tomography (CT) and MR simulation, the gros tumor volume (GTV) was delineated and prescribed 52.5 Gy in 15 fractions within the standard 40.05 Gy planning treatment volume (PTV). Treatment planning was volumetric modulated arc therapy.

Results: A total of 20 patients with multiple un-methylated MGMT glioblastoma multiforme were treated with dose-escalated radiation therapy between January 2022 and June 2023. All patients completed dose escalated radiotherapy without acute adverse effects. Progression-free survival at six months was 85%, as defined by the RANO criteria.

Conclusion: In this case series, we showed that un-methylated multiple high-grade glioma could be safely treated with dose escalation. Results of progression-free survival should be validated in a larger prospective clinical trial.

背景:2-5%的高级别胶质瘤(HGG)会同时累及多个不同的脑区,且预后不良。尽管放射治疗(RT)是治疗高级别胶质瘤的一种重要且行之有效的方法,但剂量递增放射治疗的作用仍有待确定。在本病例系列中,我们报告了接受剂量递增放射治疗的多发性未甲基化高级别胶质瘤患者的剂量测定、不良反应和反应:我们回顾了自 2022 年 1 月以来在我院接受治疗的多灶高级别胶质瘤患者的病历。所有患者均在磁共振成像(MRI)对比增强T1、T2、FLAIR序列后进行了立体定向活检,并在多学科肿瘤团队中进行了讨论。MGMT阳性患者接受了TMZ单独治疗或RT联合TMZ治疗,但不包括在本分析中。未甲基化的患者接受了不含替米唑胺(TMZ)的剂量递增 RT。在进行计算机断层扫描(CT)和磁共振模拟后,划定了大肿瘤容积(GTV),并在标准的40.05 Gy计划治疗容积(PTV)内按15个小节开出了52.5 Gy的处方。治疗计划采用容积调制弧治疗:2022年1月至2023年6月期间,共有20名多发性未甲基化MGMT胶质母细胞瘤患者接受了剂量递增放疗。所有患者均完成了剂量递增放疗,未出现急性不良反应。根据RANO标准,6个月的无进展生存率为85%:在这个病例系列中,我们发现未甲基化的多发性高级别胶质瘤可以通过剂量升级进行安全治疗。无进展生存期的结果应在更大规模的前瞻性临床试验中加以验证。
{"title":"Dose escalation with simultaneous integrated boost for un-methylated multiple glioblastoma.","authors":"Ory Haisraely, Maayan Sivan, Zvi Symon, M Ben-Ayun, L Tsvang, J Kraitman, S Dubinsky, M Siman-Tov, D Benjamin, Yaacov Lawrence, Zvi Cohen, Anton Wohl, Thila Kaisman-Elbaz, Alisa Taliansky","doi":"10.5603/rpor.100385","DOIUrl":"10.5603/rpor.100385","url":null,"abstract":"<p><strong>Background: </strong>Simultaneous involvement of multiple distinct brain regions occurs in 2-5% of all high-grade gliomas (HGG) and is associated with poor prognosis. Whereas radiotherapy (RT) is an important and well-established treatment for high-grade glioma, the role of dose-escalated radiotherapy has yet to be established. In this case series, we report upon the dosimetry, adverse effects, and response in patients with multiple un-methylated high-grade gliomas receiving dose-escalated radiation.</p><p><strong>Materials and methods: </strong>We reviewed charts of patients with multifocal high grade glioma treated at our institution since January 2022. All patients had stereotactic biopsies after an magnetic resonance imaging (MRI) contrast-enhanced with T1, T2, FLAIR sequences and were discussed in a multidisciplinary oncology team. MGMT-positive patients received either TMZ alone or RT with TMZ and were excluded from this analysis. Un-methylated patients received dose-escalated RT without temezolamide (TMZ). Following computed tomography (CT) and MR simulation, the gros tumor volume (GTV) was delineated and prescribed 52.5 Gy in 15 fractions within the standard 40.05 Gy planning treatment volume (PTV). Treatment planning was volumetric modulated arc therapy.</p><p><strong>Results: </strong>A total of 20 patients with multiple un-methylated MGMT glioblastoma multiforme were treated with dose-escalated radiation therapy between January 2022 and June 2023. All patients completed dose escalated radiotherapy without acute adverse effects. Progression-free survival at six months was 85%, as defined by the RANO criteria.</p><p><strong>Conclusion: </strong>In this case series, we showed that un-methylated multiple high-grade glioma could be safely treated with dose escalation. Results of progression-free survival should be validated in a larger prospective clinical trial.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"290-293"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe! 达拉单抗-泊马度胺联合超分次全乳腺照射是安全的!
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.100780
Kamel Debbi, Gokoulakrichenane Loganadane, Louise Roulin, Karim Belhadj, Chahrazed Boukhobza, Amira Saoudi, Noémie Grellier, Yazid Belkacemi
{"title":"Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe!","authors":"Kamel Debbi, Gokoulakrichenane Loganadane, Louise Roulin, Karim Belhadj, Chahrazed Boukhobza, Amira Saoudi, Noémie Grellier, Yazid Belkacemi","doi":"10.5603/rpor.100780","DOIUrl":"10.5603/rpor.100780","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"409-411"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of model-based dose-calculation algorithms in high dose rate brachytherapy of cervical carcinoma. 基于模型的剂量计算算法对宫颈癌高剂量率近距离放射治疗的影响。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.100778
Shraddha Srivastava, Ajay Kannathuparambil Venugopal, Moirangthem Nara Singh

Background: Task Group 43 (TG-43) formalism does not consider the tissue and applicator heterogeneities. This study is to compare the effect of model-based dose calculation algorithms, like Advanced Collapsed Cone Engine (ACE), on dose calculation with the TG-43 dose calculation formalism in patients with cervical carcinoma.

Materials and methods: 20 patients of cervical carcinoma treated with a high dose rate of intracavitary brachytherapy were prospectively studied. The target volume and organs at risk (OARs) were contoured in the Oncentra treatment planning system (Elekta, Veenendaal, The Netherlands). All patients were planned with cobalt-60 (Co-60) and iridium-192 (Ir-192) sources with doses of 21 Gy in 3 fractions. These plans were calculated with TG-43 formalism and a model-based dose calculation algorithm ACE. The dosimetric parameters of TG-43 and ACE-based plans were compared in terms of target coverage and OAR doses.

Results: For Co-60-based plans, the percentage differences in the D90 and V100 values for high-risk clinical target volume (HR-CTV) were 0.36 ± 0.43% and 0.17 ± 0.31%, respectively. For the bladder, rectum and sigmoid, the percentage differences for D2cc volumes were -0.50 ± 0.51%, -0.16 ± 0.53% and -0.37 ± 1.21%, respectively. For Ir-192-based plans, the percentage difference in the D90 for HR-CTV was 0.54 ± 0.79%, while V100 was 0.24 ± 0.29%. For the bladder, rectum and sigmoid, the doses to 2cc volume were 0.35 ± 1.06%, 0.99 ± 0.74% and 0.74 ± 1.92%, respectively. No significant differences were found in the dosimetric parameters calculated with ACE and TG-43.

Conclusion: The ACE algorithm reduced doses to OARs and targets. However, ACE and TG-43 did not show significant differences in the dosimetric parameters of the target and OARs with both sources.

背景:第43工作组(TG-43)的形式不考虑组织和施术者的异质性。本研究旨在比较基于模型的剂量计算算法(如高级塌陷锥体引擎(ACE))与 TG-43 剂量计算形式对宫颈癌患者剂量计算的影响。在 Oncentra 治疗计划系统(Elekta, Veenendaal, The Netherlands)中对靶体积和危险器官(OARs)进行了轮廓分析。所有患者都计划使用钴-60(Co-60)和铱-192(Ir-192)放射源,剂量为 21 Gy,分 3 次进行。这些计划采用 TG-43 形式和基于模型的剂量计算算法 ACE 进行计算。比较了基于 TG-43 和基于 ACE 的计划在靶区覆盖和 OAR 剂量方面的剂量学参数:结果:对于基于 Co-60 的计划,高风险临床靶体积(HR-CTV)的 D90 和 V100 值的百分比差异分别为 0.36 ± 0.43% 和 0.17 ± 0.31%。对于膀胱、直肠和乙状结肠,D2cc容积的百分比差异分别为-0.50 ± 0.51%、-0.16 ± 0.53%和-0.37 ± 1.21%。对于基于 Ir-192 的计划,HR-CTV 的 D90 百分比差异为 0.54 ± 0.79%,而 V100 百分比差异为 0.24 ± 0.29%。膀胱、直肠和乙状结肠的 2cc 容量剂量分别为 0.35 ± 1.06%、0.99 ± 0.74% 和 0.74 ± 1.92%。用 ACE 和 TG-43 计算的剂量学参数无明显差异:结论:ACE算法减少了OAR和目标的剂量。结论:ACE 算法减少了 OAR 和目标的剂量,但 ACE 和 TG-43 计算出的目标和 OAR 的剂量学参数与这两种放射源并无显著差异。
{"title":"Effect of model-based dose-calculation algorithms in high dose rate brachytherapy of cervical carcinoma.","authors":"Shraddha Srivastava, Ajay Kannathuparambil Venugopal, Moirangthem Nara Singh","doi":"10.5603/rpor.100778","DOIUrl":"10.5603/rpor.100778","url":null,"abstract":"<p><strong>Background: </strong>Task Group 43 (TG-43) formalism does not consider the tissue and applicator heterogeneities. This study is to compare the effect of model-based dose calculation algorithms, like Advanced Collapsed Cone Engine (ACE), on dose calculation with the TG-43 dose calculation formalism in patients with cervical carcinoma.</p><p><strong>Materials and methods: </strong>20 patients of cervical carcinoma treated with a high dose rate of intracavitary brachytherapy were prospectively studied. The target volume and organs at risk (OARs) were contoured in the Oncentra treatment planning system (Elekta, Veenendaal, The Netherlands). All patients were planned with cobalt-60 (Co-60) and iridium-192 (Ir-192) sources with doses of 21 Gy in 3 fractions. These plans were calculated with TG-43 formalism and a model-based dose calculation algorithm ACE. The dosimetric parameters of TG-43 and ACE-based plans were compared in terms of target coverage and OAR doses.</p><p><strong>Results: </strong>For Co-60-based plans, the percentage differences in the D90 and V100 values for high-risk clinical target volume (HR-CTV) were 0.36 ± 0.43% and 0.17 ± 0.31%, respectively. For the bladder, rectum and sigmoid, the percentage differences for D2cc volumes were -0.50 ± 0.51%, -0.16 ± 0.53% and -0.37 ± 1.21%, respectively. For Ir-192-based plans, the percentage difference in the D90 for HR-CTV was 0.54 ± 0.79%, while V100 was 0.24 ± 0.29%. For the bladder, rectum and sigmoid, the doses to 2cc volume were 0.35 ± 1.06%, 0.99 ± 0.74% and 0.74 ± 1.92%, respectively. No significant differences were found in the dosimetric parameters calculated with ACE and TG-43.</p><p><strong>Conclusion: </strong>The ACE algorithm reduced doses to OARs and targets. However, ACE and TG-43 did not show significant differences in the dosimetric parameters of the target and OARs with both sources.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"300-308"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved dose compensation model owing to short irradiation interruption time for hypoxic tumor using a microdosimetric kinetic model. 利用微剂量测定动力学模型改进缺氧肿瘤的剂量补偿模型,缩短辐照中断时间。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.101098
Daisuke Kawahara

Background: The objective was to enhance the biological compensation factor related to irradiation interruption in a short time (short irradiation interruption) in hypoxic tumors using a refined microdosimetric kinetic model (MKM) for photon radiation therapy.

Materials and methods: The biological dose differences were calculated for CHO-K1 cells exposed to a photon beam, considering interruptions of (τ) of 0-120 min and pO2 at oxygen levels of 0.075-160 mm Hg. The interrupted dose fraction (IDF) was defined as the percentage ratio of the dose delivered before short irradiation interruption to the total dose, which ranged from 10-90%. The compensated dose was calculated based on an IDF of 10-90% for a dose of 2-8 Gy and oxygen levels of 0.075-160 mm Hg.

Results: The Δ with and without short irradiation interruption was more pronounced with a higher dose and increased pO2. It exceeded 3% between IDF of 50% and either 10% or 90% and occurred more than τ = 50 min at 0.075 mm Hg, τ = 20 min at 3 mm Hg, τ = 20 min at 8 mm Hg, τ = 20 min at 15 mm Hg, τ = 20 min at 38 mm Hg, and τ = 20 min at 160 mm Hg. The dose compensation factor was greater at higher IDF rates.

Conclusion: The biological dose decreased with longer interruption times and higher oxygen concentrations. The improved model can compensate for the biological doses at various oxygen concentrations.

Advances in knowledge: The current study improved the dose compensation method for the decrease in the biological effect owing to short irradiation interruption by considering the oxygen concentration.

研究背景目的是利用光子放射治疗的微剂量测定动力学模型(MKM),在短时间内(短照射中断)提高缺氧肿瘤中与照射中断相关的生物补偿因子:计算了接受光子束照射的 CHO-K1 细胞的生物剂量差异,考虑了 0-120 分钟的中断时间(τ)和 0.075-160 mm Hg 的氧水平 pO2。中断剂量分数(IDF)的定义是短时间辐照中断前的剂量占总剂量的百分比,范围在10%-90%之间。补偿剂量是根据剂量为2-8 Gy、氧水平为0.075-160 mm Hg时的IDF为10-90%计算得出的:结果:剂量越大、血氧饱和度越高,短时间中断照射和不中断照射时的Δ越明显。在 IDF 为 50%、10% 或 90% 之间,Δ超过了 3%,在 0.075 mm Hg 时,τ = 50 分钟;在 3 mm Hg 时,τ = 20 分钟;在 8 mm Hg 时,τ = 20 分钟;在 15 mm Hg 时,τ = 20 分钟;在 38 mm Hg 时,τ = 20 分钟;在 160 mm Hg 时,τ = 20 分钟。IDF率越高,剂量补偿系数越大:结论:中断时间越长、氧气浓度越高,生物剂量越小。改进后的模型可以补偿不同氧气浓度下的生物剂量:本研究通过考虑氧气浓度,改进了辐照短时间中断导致生物效应下降的剂量补偿方法。
{"title":"Improved dose compensation model owing to short irradiation interruption time for hypoxic tumor using a microdosimetric kinetic model.","authors":"Daisuke Kawahara","doi":"10.5603/rpor.101098","DOIUrl":"10.5603/rpor.101098","url":null,"abstract":"<p><strong>Background: </strong>The objective was to enhance the biological compensation factor related to irradiation interruption in a short time (short irradiation interruption) in hypoxic tumors using a refined microdosimetric kinetic model (MKM) for photon radiation therapy.</p><p><strong>Materials and methods: </strong>The biological dose differences were calculated for CHO-K1 cells exposed to a photon beam, considering interruptions of (τ) of 0-120 min and pO<sub>2</sub> at oxygen levels of 0.075-160 mm Hg. The interrupted dose fraction (IDF) was defined as the percentage ratio of the dose delivered before short irradiation interruption to the total dose, which ranged from 10-90%. The compensated dose was calculated based on an IDF of 10-90% for a dose of 2-8 Gy and oxygen levels of 0.075-160 mm Hg.</p><p><strong>Results: </strong>The Δ with and without short irradiation interruption was more pronounced with a higher dose and increased pO<sub>2</sub>. It exceeded 3% between IDF of 50% and either 10% or 90% and occurred more than τ = 50 min at 0.075 mm Hg, τ = 20 min at 3 mm Hg, τ = 20 min at 8 mm Hg, τ = 20 min at 15 mm Hg, τ = 20 min at 38 mm Hg, and τ = 20 min at 160 mm Hg. The dose compensation factor was greater at higher IDF rates.</p><p><strong>Conclusion: </strong>The biological dose decreased with longer interruption times and higher oxygen concentrations. The improved model can compensate for the biological doses at various oxygen concentrations.</p><p><strong>Advances in knowledge: </strong>The current study improved the dose compensation method for the decrease in the biological effect owing to short irradiation interruption by considering the oxygen concentration.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"271-279"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of glass compression plate on EBT-XD film dosimetry for pretreatment quality assurance of stereotactic body radiotherapy. 玻璃压缩板对用于立体定向体放射治疗预处理质量保证的 EBT-XD 胶片剂量测定的影响。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.101095
Sathiya Raj, Nithya Shree, K M Ganesh

Background: EBT-XD film specially designed for high dose verifications such as stereotactic treatments. The dose response of the film can be affected by several factors, the curly nature of the film being one of them. In this study this curly nature of the film was investigated for stereotactic body radiotherapy (SBRT) plan verifications.

Materials and methods: For this study, 18 SBRT (11 prostate, 3 spines, and 4 lungs) cases were enrolled. For all the cases, VMAT plans were created in the Monaco treatment planning system and plan was delivered in Elekta Versa HD linear accelerator and delivered fluence was captured by EBT-XD films. All films were scanned with and without a compression plate. All the films were analyzed using the single-channel film method using the red channel.

Results: A significant difference in the gamma passing rates (GPR) for the films scanned with and without the compression plate was observed. The maximum percentage differences in GPR between using and not using a compression plate were 12.7% for 1% 1 mm, 8.1% for 2% 2 mm, 7.5% for 3% 2 mm, and 5% for 3% 3mm criteria. Similarly, the mean %difference in GPR was 5.8% for 1% 1 mm, 2.4% for 2% 2 mm, 1.6% for 3% 2 mm and 0.96% for 3% 3 mm criteria.

Conclusion: The results suggest that placing a compression plate over the film during scanning provided a great advantage in achieving a more accurate gamma passing rate irrespective of gamma criteria.

背景:EBT-XD 胶片专为立体定向治疗等高剂量验证而设计。胶片的剂量响应会受到多种因素的影响,胶片的卷曲特性就是其中之一。本研究针对立体定向体放射治疗(SBRT)计划验证,对胶片的卷曲特性进行了调查:本研究共收集了 18 个 SBRT 病例(11 个前列腺病例、3 个脊柱病例和 4 个肺部病例)。所有病例均在 Monaco 治疗计划系统中创建了 VMAT 计划,计划在 Elekta Versa HD 直线加速器中实施,并通过 EBT-XD 胶片捕获了释放的能量。所有胶片均在使用或不使用压缩板的情况下进行扫描。所有胶片均采用单通道胶片法,使用红色通道进行分析:结果:使用和不使用压缩板扫描的胶片在伽马通过率(GPR)方面存在明显差异。使用压缩板和不使用压缩板的伽马通过率差异最大,1% 1 毫米为 12.7%,2% 2 毫米为 8.1%,3% 2 毫米为 7.5%,3% 3 毫米为 5%。同样,1% 1 毫米、2% 2 毫米、3% 2 毫米和 3% 3 毫米标准的 GPR 平均差异率分别为 5.8%、2.4%、1.6% 和 0.96%:结果表明,在扫描过程中在胶片上放置一个压缩板对获得更准确的伽马通过率有很大的好处,而与伽马标准无关。
{"title":"Effect of glass compression plate on EBT-XD film dosimetry for pretreatment quality assurance of stereotactic body radiotherapy.","authors":"Sathiya Raj, Nithya Shree, K M Ganesh","doi":"10.5603/rpor.101095","DOIUrl":"10.5603/rpor.101095","url":null,"abstract":"<p><strong>Background: </strong>EBT-XD film specially designed for high dose verifications such as stereotactic treatments. The dose response of the film can be affected by several factors, the curly nature of the film being one of them. In this study this curly nature of the film was investigated for stereotactic body radiotherapy (SBRT) plan verifications.</p><p><strong>Materials and methods: </strong>For this study, 18 SBRT (11 prostate, 3 spines, and 4 lungs) cases were enrolled. For all the cases, VMAT plans were created in the Monaco treatment planning system and plan was delivered in Elekta Versa HD linear accelerator and delivered fluence was captured by EBT-XD films. All films were scanned with and without a compression plate. All the films were analyzed using the single-channel film method using the red channel.</p><p><strong>Results: </strong>A significant difference in the gamma passing rates (GPR) for the films scanned with and without the compression plate was observed. The maximum percentage differences in GPR between using and not using a compression plate were 12.7% for 1% 1 mm, 8.1% for 2% 2 mm, 7.5% for 3% 2 mm, and 5% for 3% 3mm criteria. Similarly, the mean %difference in GPR was 5.8% for 1% 1 mm, 2.4% for 2% 2 mm, 1.6% for 3% 2 mm and 0.96% for 3% 3 mm criteria.</p><p><strong>Conclusion: </strong>The results suggest that placing a compression plate over the film during scanning provided a great advantage in achieving a more accurate gamma passing rate irrespective of gamma criteria.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"357-361"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of hypofractionated radiotherapy versus conventional fractionated radiotherapy in diffuse intrinsic pontine glioma: A systematic review and meta-analysis. 弥漫性桥脑胶质瘤低分次放疗与传统分次放疗的疗效和安全性:系统综述与荟萃分析。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.100779
Gustavo A Viani, Andre G Gouveia, Fabio Arcidiacono, Gustavo N Marta, Ana Carolina Hamamura, Paola Anselmo, Felipe S Barbosa, Fabio Y Moraes

Background: Diffuse intrinsic pontine glioma (DIPG) stands as the predominant type of brainstem glioma. It is characterized by a notably brief median survival period, with the majority of patients experiencing disease progression within six months following radiation therapy. This systematic review and meta-analysis aims to assess the efficacy and safety of hypofractionated radiotherapy (HFRT) compared to conventionally fractionated radiotherapy (CFRT) in DIPG treatment.

Materials and methods: A systematic literature search was conducted in four databases, and relevant studies comparing HFRT and CFRT in DIPG were included. Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), and treatment-related toxicities. Statistical analysis was performed using random-effects models with heterogeneity assessment.

Results: Five studies met the inclusion criteria, comprising 518 patients. No significant difference in one-year OS was observed between HFRT and CFRT (29% vs. 22%, p = 0.94). The median OS was similar in both treatment groups (9.7 vs. 9.3 months, p = 0.324). Similarly, no significant difference in one-year PFS was found between HFRT and CFRT (19.8% vs. 16.6%, p = 0.82), with comparable median PFS (9.3 vs. 9.4 months, p = 0.20). In meta-regression analysis, there was no association of chemotherapy (p > 0.05) or radiation biologically effective dose (BED) (p > 0.05) regarding OS or PFS outcomes. There were no significant differences in treatment-related toxicities.

Conclusions: HFRT yields one-year OS and PFS rates similar to CFRT in DIPG, with no significant differences in treatment-related toxicities. Chemotherapy and BED did not affect OS or PFS.

背景:弥漫性桥脑胶质瘤(DIPG)是脑干胶质瘤的主要类型。它的特点是中位生存期很短,大多数患者在放疗后六个月内疾病进展。本系统综述和荟萃分析旨在评估低分次放射治疗(HFRT)与常规分次放射治疗(CFRT)相比在DIPG治疗中的有效性和安全性:在四个数据库中进行了系统性文献检索,纳入了比较HFRT和CFRT治疗DIPG的相关研究。提取数据并分析总生存期(OS)、无进展生存期(PFS)和治疗相关毒性反应。采用随机效应模型进行统计分析,并进行异质性评估:结果:五项研究符合纳入标准,共纳入 518 名患者。HFRT和CFRT的一年OS无明显差异(29% vs. 22%,P = 0.94)。两个治疗组的中位 OS 相似(9.7 个月 vs. 9.3 个月,p = 0.324)。同样,HFRT 和 CFRT 的一年生存期也无明显差异(19.8% vs. 16.6%,p = 0.82),中位生存期也相当(9.3 vs. 9.4 个月,p = 0.20)。在元回归分析中,化疗(p > 0.05)或放射生物有效剂量(BED)(p > 0.05)与OS或PFS结果没有关联。治疗相关毒性无明显差异:结论:HFRT在DIPG中的一年OS和PFS率与CFRT相似,治疗相关毒性无显著差异。化疗和BED对OS和PFS没有影响。
{"title":"Efficacy and safety of hypofractionated radiotherapy versus conventional fractionated radiotherapy in diffuse intrinsic pontine glioma: A systematic review and meta-analysis.","authors":"Gustavo A Viani, Andre G Gouveia, Fabio Arcidiacono, Gustavo N Marta, Ana Carolina Hamamura, Paola Anselmo, Felipe S Barbosa, Fabio Y Moraes","doi":"10.5603/rpor.100779","DOIUrl":"10.5603/rpor.100779","url":null,"abstract":"<p><strong>Background: </strong>Diffuse intrinsic pontine glioma (DIPG) stands as the predominant type of brainstem glioma. It is characterized by a notably brief median survival period, with the majority of patients experiencing disease progression within six months following radiation therapy. This systematic review and meta-analysis aims to assess the efficacy and safety of hypofractionated radiotherapy (HFRT) compared to conventionally fractionated radiotherapy (CFRT) in DIPG treatment.</p><p><strong>Materials and methods: </strong>A systematic literature search was conducted in four databases, and relevant studies comparing HFRT and CFRT in DIPG were included. Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), and treatment-related toxicities. Statistical analysis was performed using random-effects models with heterogeneity assessment.</p><p><strong>Results: </strong>Five studies met the inclusion criteria, comprising 518 patients. No significant difference in one-year OS was observed between HFRT and CFRT (29% <i>vs.</i> 22%, p = 0.94). The median OS was similar in both treatment groups (9.7 <i>vs.</i> 9.3 months, p = 0.324). Similarly, no significant difference in one-year PFS was found between HFRT and CFRT (19.8% <i>vs.</i> 16.6%, p = 0.82), with comparable median PFS (9.3 <i>vs.</i> 9.4 months, p = 0.20). In meta-regression analysis, there was no association of chemotherapy (p > 0.05) or radiation biologically effective dose (BED) (p > 0.05) regarding OS or PFS outcomes. There were no significant differences in treatment-related toxicities.</p><p><strong>Conclusions: </strong>HFRT yields one-year OS and PFS rates similar to CFRT in DIPG, with no significant differences in treatment-related toxicities. Chemotherapy and BED did not affect OS or PFS.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"309-317"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation-induced skin injury in the head and neck region: pathogenesis, clinics, prevention, treatment considerations and proposal for management algorithm. 辐射导致的头颈部皮肤损伤:发病机制、临床、预防、治疗注意事项和管理算法建议。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.100775
Jakub Pazdrowski, Justyna Gornowicz-Porowska, Joanna Kaźmierska, Violetta Krajka-Kuźniak, Adriana Polanska, Michał Masternak, Mateusz Szewczyk, Wojciech Golusiński, Aleksandra Danczak-Pazdrowska

Worldwide increase of head and neck cancers ranks these malignancies among top causes of cancer in human population. Radiation induced skin injury (RISI) is one of the major side effects of radiotherapy (RT). Skin of the neck is exposed to radiation due to necessity of therapeutic or prophylactic (elective) irradiation of neck lymph nodes and target organs, including the larynx and hypopharynx. The location of the neck exposes these regions of the skin to various additional exposomes such as ultraviolet radiation (UVR), pollution and cigarette smoke. There are many controversies or inconsistencies regarding RISI, from molecular aspects and therapy to terminology. There is lack of high-quality and large-sample studies in both forms of RISI: acute (aRISI) and chronic (cRISI). Finally, no gold standards in the management of aRISI and cRISI have been established yet. In this article, the authors discuss the pathogenesis, clinical picture, prevention and clinical interventions and present a proposed treatment algorithm.

头颈部癌症在全球范围内的发病率呈上升趋势,是导致人类罹患癌症的主要原因之一。放射性皮肤损伤(RISI)是放射治疗(RT)的主要副作用之一。由于需要对颈部淋巴结和包括喉部和下咽在内的靶器官进行治疗性或预防性(选择性)照射,颈部皮肤会受到辐射。颈部的位置使这些区域的皮肤暴露于紫外线辐射(UVR)、污染和香烟烟雾等各种额外的暴露体。关于 RISI,从分子方面、治疗方法到术语,都存在许多争议或不一致之处。缺乏对两种形式的 RISI(急性(aRISI)和慢性(cRISI))的高质量和大样本研究。最后,aRISI 和 cRISI 治疗的金标准尚未确立。在本文中,作者讨论了发病机制、临床表现、预防和临床干预措施,并提出了一种拟议的治疗算法。
{"title":"Radiation-induced skin injury in the head and neck region: pathogenesis, clinics, prevention, treatment considerations and proposal for management algorithm.","authors":"Jakub Pazdrowski, Justyna Gornowicz-Porowska, Joanna Kaźmierska, Violetta Krajka-Kuźniak, Adriana Polanska, Michał Masternak, Mateusz Szewczyk, Wojciech Golusiński, Aleksandra Danczak-Pazdrowska","doi":"10.5603/rpor.100775","DOIUrl":"10.5603/rpor.100775","url":null,"abstract":"<p><p>Worldwide increase of head and neck cancers ranks these malignancies among top causes of cancer in human population. Radiation induced skin injury (RISI) is one of the major side effects of radiotherapy (RT). Skin of the neck is exposed to radiation due to necessity of therapeutic or prophylactic (elective) irradiation of neck lymph nodes and target organs, including the larynx and hypopharynx. The location of the neck exposes these regions of the skin to various additional exposomes such as ultraviolet radiation (UVR), pollution and cigarette smoke. There are many controversies or inconsistencies regarding RISI, from molecular aspects and therapy to terminology. There is lack of high-quality and large-sample studies in both forms of RISI: acute (aRISI) and chronic (cRISI). Finally, no gold standards in the management of aRISI and cRISI have been established yet. In this article, the authors discuss the pathogenesis, clinical picture, prevention and clinical interventions and present a proposed treatment algorithm.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"373-390"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design and performance validation of a novel 3d printed thin-walled and transparent electron beam applicators for intraoperative radiation therapy with beam energy up to 12 MeV. 用于术中放射治疗的新型 3d 打印薄壁透明电子束应用器的设计与性能验证,束流能量高达 12 MeV。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.5603/rpor.101092
Agnieszka Misiarz, Aleksandra Lenartowicz, Przemysław Adrich, Jacek Rzadkiewicz, Sławomir Wronka, Jan Trzuskowski, Marta Kruszyna-Mochalska, Bartosz Urbański, Beata Adamczyk, Jacek Pracz

A high-energy electron accelerator is used in the treatment of patients in the so-called intraoperative electron radiotherapy (IOERT). The work aimed to present the results of the validation of a new design of an electron beam applicator for use in IOERT. A novel solution was described along with the design optimization method based on Monte Carlo simulations. In this solution, the applicator consists of two parts. The lower exchangeable part collimates the therapeutic field. Measurements were made based on the International Electrotechnical Commission (IEC) standard recommendations. The measurement described in the standard has been adapted to the specificity of the intraoperative accelerator Source to Skin Distance - of 60 cm and applicators with a circular cross-sectional area. Measurements were performed for nominal beam energies of 6, 10, and 12 MeV and two therapeutic field diameters of 6 and 10 cm. The dose due to stray X-ray radiation in all energies is less than 0.3% and increases for energies from 6 to 12 MeV by 2.9 times from 0.1 for 6MeV to 0.29 for 12 MeV. The average dose due to leakage radiation also shows an increasing trend and is higher for a 6 cm diameter applicator. Validation confirmed the usefulness of the novel applicator design for clinical applications. Thanks to the use of 3D printing, it was possible to make applicators that are transparent, biocompatible and, at the same time, light and form a beam field with therapeutically useful accuracy, and the leakage radiation does not exceed normative recommendations.

在所谓的术中电子放射治疗(IOERT)中,高能电子加速器被用于治疗病人。这项工作旨在展示用于术中电子放疗的电子束应用器新设计的验证结果。在蒙特卡洛模拟的基础上,介绍了一种新的解决方案和设计优化方法。在该方案中,涂抹器由两部分组成。下部的可交换部分对治疗场进行准直。测量是根据国际电工委员会(IEC)的标准建议进行的。标准中描述的测量方法已根据术中加速器的特殊性进行了调整,即源到皮肤的距离为 60 厘米,涂抹器的横截面积为圆形。测量针对的是 6、10 和 12 MeV 的标称束流能量以及 6 厘米和 10 厘米的两个治疗场直径。在所有能量下,杂散 X 射线辐射造成的剂量都小于 0.3%,而在 6 至 12 MeV 能量下,杂散 X 射线辐射造成的剂量增加了 2.9 倍,从 6 MeV 的 0.1 到 12 MeV 的 0.29。泄漏辐射造成的平均剂量也呈上升趋势,直径为 6 厘米的涂抹器的平均剂量更高。验证证实了新型涂抹器设计在临床应用中的实用性。由于使用了三维打印技术,因此可以制造出透明、生物相容性好的涂抹器,同时还具有轻质、可形成具有治疗作用的精确射束场以及泄漏辐射不超过规范建议的特点。
{"title":"Design and performance validation of a novel 3d printed thin-walled and transparent electron beam applicators for intraoperative radiation therapy with beam energy up to 12 MeV.","authors":"Agnieszka Misiarz, Aleksandra Lenartowicz, Przemysław Adrich, Jacek Rzadkiewicz, Sławomir Wronka, Jan Trzuskowski, Marta Kruszyna-Mochalska, Bartosz Urbański, Beata Adamczyk, Jacek Pracz","doi":"10.5603/rpor.101092","DOIUrl":"10.5603/rpor.101092","url":null,"abstract":"<p><p>A high-energy electron accelerator is used in the treatment of patients in the so-called intraoperative electron radiotherapy (IOERT). The work aimed to present the results of the validation of a new design of an electron beam applicator for use in IOERT. A novel solution was described along with the design optimization method based on Monte Carlo simulations. In this solution, the applicator consists of two parts. The lower exchangeable part collimates the therapeutic field. Measurements were made based on the International Electrotechnical Commission (IEC) standard recommendations. The measurement described in the standard has been adapted to the specificity of the intraoperative accelerator Source to Skin Distance - of 60 cm and applicators with a circular cross-sectional area. Measurements were performed for nominal beam energies of 6, 10, and 12 MeV and two therapeutic field diameters of 6 and 10 cm. The dose due to stray X-ray radiation in all energies is less than 0.3% and increases for energies from 6 to 12 MeV by 2.9 times from 0.1 for 6MeV to 0.29 for 12 MeV. The average dose due to leakage radiation also shows an increasing trend and is higher for a 6 cm diameter applicator. Validation confirmed the usefulness of the novel applicator design for clinical applications. Thanks to the use of 3D printing, it was possible to make applicators that are transparent, biocompatible and, at the same time, light and form a beam field with therapeutically useful accuracy, and the leakage radiation does not exceed normative recommendations.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"329-339"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reports of Practical Oncology and Radiotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1